NCT06548360

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 2 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Conditions

• NonSegmental Vitiligo

Interventions

Type	Name	Description
DRUG	Ruxolitinib Cream	Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
DRUG	Vehicle Cream	Matching vehicle cream applied topically to the affected area as a thin film twice daily.

Timeline

• Start date: 2025-01-24
• Primary completion: 2026-08-10
• Completion: 2027-03-13
• First posted: 2024-08-12
• Last updated: 2025-12-18

Locations

99 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study